Cancers, Vol. 16, Pages 426: The Impact of the COVID-19 Pandemic on Adherence to Endocrine Therapy for Breast Cancer in Catalonia (Spain)
Conclusions. The COVID-19 pandemic had only a modest impact on adherence to endocrine therapy (≈3%), despite the enormous disruptions for patients, the healthcare system in general, and cancer care in particular that were occurring in that period. (Source: Cancers)
Source: Cancers - January 19, 2024 Category: Cancer & Oncology Authors: Aurea Navarro-Sabate Rebeca Font Fina Mart ínez-Soler Judit Sol à Avelina Tortosa Josepa Ribes Ll úcia Benito-Aracil Josep Alfons Espinas Josep Maria Borras Tags: Article Source Type: research
Efficacy of CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2 − breast cancer: an umbrella review
ConclusionsBased on current evidence, CDK4/6 inhibitors combined with ET have great confidence in improving PFS, OS, ORR, and CBR outcomes in patients with ABC, which provides more rational and valid evidence-based medicine for CDK4/6 inhibitor promotion and clinical decision support. (Source: Journal of Cancer Research and Clinical Oncology)
Source: Journal of Cancer Research and Clinical Oncology - January 19, 2024 Category: Cancer & Oncology Source Type: research
Combination of Palbociclib and Endocrine Therapy in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With or Without Brain Metastases
CONCLUSIONS: Palbociclib plus endocrine therapy in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer was effective and well-tolerated, even in patients with brain metastases. More benefits were observed in frontline therapy, chemotherapy-naive, and endocrine therapy-sensitive patients with fewer metastatic sites.PMID:38233376 | PMC:PMC10798105 | DOI:10.1177/15330338231206986 (Source: Technology in Cancer Research and Treatment)
Source: Technology in Cancer Research and Treatment - January 17, 2024 Category: Cancer & Oncology Authors: Qiuyi Zhang Xiaofeng Lan Jiayi Huang Xiaofeng Xie Liping Chen Lin Song Xue Bai Xuelian Chen Haiman Jing Caiwen Du Source Type: research
Identification of patient subgroups who benefit from a behavioral intervention to improve adjuvant endocrine therapy adherence: a randomized-controlled trial
ConclusionsA subgroup of patients who received STRIDE exhibited improvements in AET adherence. The interrelatedness of moderators suggests an underlying profile of patients with lower symptom burden who benefitted most from the intervention.Study registrationNCT03837496. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 17, 2024 Category: Cancer & Oncology Source Type: research
Interventions to improve oral endocrine therapy adherence in breast cancer patients
ConclusionsWhile the interventions tested so far have shown to improve OET adherence in HR+ BC patients in some studies, there is a need to design combination interventions addressing multiple barriers in this population.Implications for Cancer SurvivorsThis study showcases effectiveness of novel interventions to improve OET adherence and the need to further develop patient-centered strategies to benefit all patients with HR+ BC. (Source: Journal of Cancer Survivorship)
Source: Journal of Cancer Survivorship - January 17, 2024 Category: Cancer & Oncology Source Type: research
Clinical considerations of CDK4/6 inhibitors in HER2 positive breast cancer
Deregulation of cell cycles can result in a variety of cancers, including breast cancer (BC). In fact, abnormal regulation of cell cycle pathways is often observed in breast cancer, leading to malignant cell proliferation. CDK4/6 inhibitors (CDK4/6i) can block the G1 cell cycle through the cyclin D-cyclin dependent kinase 4/6-inhibitor of CDK4-retinoblastoma (cyclinD-CDK4/6-INK4-RB) pathway, thus blocking the proliferation of invasive cells, showing great therapeutic potential to inhibit the spread of BC. So far, three FDA-approved drugs have been shown to be effective in the management of advanced hormone receptor positiv...
Source: Frontiers in Oncology - January 16, 2024 Category: Cancer & Oncology Source Type: research
Endosomal recycling inhibitors downregulate estrogen receptor-alpha and synergise with endocrine therapies
DiscussionOur data suggest that combining ERIs with hormone receptor antagonists may enhance their efficacy and reduce the emergence of drug resistance. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 16, 2024 Category: Cancer & Oncology Source Type: research
The adverse events of CDK4/6 inhibitors for HR+/ HER2- breast cancer: an umbrella review of meta-analyses of randomized controlled trials
Conclusion: The AEs associated with CDK4/6 inhibitors vary, necessitating individualized and precise clinical selection for optimal management. This approach should be based on the patient’s medical history and the distinct characteristics of different CDK4/6 inhibitors to improve the patient’s quality of life.Systematic Review Registration: [https://systematicreview.gov/], identifier [CRD42022350167] (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - January 15, 2024 Category: Drugs & Pharmacology Source Type: research
Long-term patient-reported outcomes from monarchE: abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer
In monarchE, abemaciclib demonstrated a sustained benefit in invasive disease-free survival and a tolerable safety profile at 42-months median follow-up. With no expected disease-related symptoms, therapies in the adjuvant setting should preserve quality of life (QoL). With all patients off abemaciclib, we report updated patient-reported outcomes (PROs) for the full 2-year treatment period and follow-up. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 15, 2024 Category: Cancer & Oncology Authors: Sara M. Tolaney, Valentina Guarneri, Jae Hong Seo, Josefina Cruz, Miguel Henriques Abreu, Masato Takahashi, Carlos Barrios, Kristi McIntyre, Ran Wei, Maria Munoz, Belen San Antonio, Astra M. Liepa, Miguel Martin, Stephen R.D. Johnston, Pirkko-Liisa Kellok Tags: Original Research Source Type: research
Factors influencing the first and the fifth years adherence to adjuvant endocrine therapy in breast cancer patients in a low income country
ConclusionThe proportion of patients who are not adherent to AET was high in both cohorts, and the rate of non-adherent patients rises over time. It is essential to incorporate screening methods for lack of compliance to AET, as well as measures to try to reduce non-persistence to the treatment, such as educating the patients on the benefits of the treatment, managing comorbidities through lifestyle changes and, therefore, reducing polypharmacy and, above all, detecting and treating very early the adverse effects of AET that might interfere with its correct use. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 15, 2024 Category: Cancer & Oncology Source Type: research
Targeting systemic and gut microbial metabolism in ER < sup > + < /sup > breast cancer
Trends Endocrinol Metab. 2024 Jan 13:S1043-2760(23)00273-4. doi: 10.1016/j.tem.2023.12.008. Online ahead of print.ABSTRACTEstrogen receptor-positive (ER+) breast tumors have a better overall prognosis than ER- tumors; however, there is a sustained risk of recurrence. Mounting evidence indicates that genetic and epigenetic changes associated with resistance impact critical signaling pathways governing cell metabolism. This review delves into recent literature concerning the metabolic pathways regulated in ER+ breast tumors by the availability of nutrients and endocrine therapies and summarizes research on how changes in sys...
Source: Trends in Endocrinology and Metabolism: TEM - January 14, 2024 Category: Endocrinology Authors: Hannah Heath Ayca Nazli Mogol Ashlie Santaliz Casiano Qianying Zuo Zeynep Madak-Erdogan Source Type: research
Cancers, Vol. 16, Pages 339: The Magee 3 Equation Predicts Favorable Pathologic Response to Neoadjuvant Endocrine Therapy in Breast Cancer Patients
Conclusions: Patients with ME3 &lt; 20 have a higher likelihood of presenting a pathological response, offering a cost-effective alternative tool to Oncotype DX. Larger future studies with a prospective design are awaited to confirm our findings. (Source: Cancers)
Source: Cancers - January 13, 2024 Category: Cancer & Oncology Authors: Carlos Eduardo Paiva Maria Paola Montesso Zonta Rafaela Carvalho Granero Vitor Souza Guimar ães Layla Melo Pimenta Gustavo Ramos Teixeira Bianca Sakamoto Ribeiro Paiva Tags: Communication Source Type: research
Endocrine therapy for cancer
Endocrine therapy is widely used to treat cancers whose growth is dependent on hormonal stimulation, most commonly breast, prostate and endometrial cancers. The principles behind its use, indications, different medications available and some of the evidence to support its use are described. Endocrine therapies avoid the toxicities associated with chemotherapy, but do have recognized side effects that can impact on quality of life. (Source: Surgery (Medicine Publishing))
Source: Surgery (Medicine Publishing) - January 12, 2024 Category: Surgery Authors: Kenneth Elder, J. Michael Dixon, Majid Rashid, James P. Blackmur, Jacqueline Laurie Tags: Cancer treatment Source Type: research
Treatment patterns of patients with HR+/HER2- metastatic breast cancer receiving CDK4/6 inhibitor-based regimens: a cohort study in the French nationwide healthcare database
ConclusionThis real-world analysis confirms the effectiveness of CDK4/6 inhibitor-based regimens in French patients and highlights the frequent use of chemotherapy as second line therapy. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 11, 2024 Category: Cancer & Oncology Source Type: research
A comprehensive review on the applications of ferrite nanoparticles in the diagnosis and treatment of breast cancer
AbstractVarious conventional treatments including endocrine therapy, radiotherapy, surgery, and chemotherapy have been used for several decades to treat breast cancer; however, these therapies exhibit various life-threatening and debilitating adverse effects in patients. Additionally, combination therapies are required for prompt action as well as to prevent drug resistance toward standard breast cancer medications. Ferrite nanoparticles (NPs) are increasingly gaining momentum for their application in the diagnosis and treatment of breast cancer. Spinel ferrites are particularly used against breast cancer and have shown in...
Source: Medical Oncology - January 10, 2024 Category: Cancer & Oncology Source Type: research
